Mettler-Toledo International Inc. (0K10.L)
USD 991.96
(-4.33%)
USD 991.96
(-4.33%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 385.86 Million USD | -12.64% |
| 2022 | 441.69 Million USD | 6.55% |
| 2021 | 414.54 Million USD | 39.29% |
| 2020 | 297.61 Million USD | 8.5% |
| 2019 | 274.28 Million USD | 2.03% |
| 2018 | 268.82 Million USD | 5.26% |
| 2017 | 255.39 Million USD | 15.02% |
| 2016 | 222.04 Million USD | 3.57% |
| 2015 | 214.38 Million USD | 4.82% |
| 2014 | 204.53 Million USD | -2.8% |
| 2013 | 210.41 Million USD | 5.77% |
| 2012 | 198.93 Million USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 373.67 Million USD | -3.16% |
| 2024 Q2 | 366.39 Million USD | -1.95% |
| 2023 FY | 385.86 Million USD | -12.64% |
| 2023 Q4 | 385.86 Million USD | 2.63% |
| 2023 Q1 | 427.54 Million USD | -3.2% |
| 2023 Q2 | 394.95 Million USD | -7.62% |
| 2023 Q3 | 375.95 Million USD | -4.81% |
| 2022 Q1 | 446.49 Million USD | 7.71% |
| 2022 Q4 | 441.69 Million USD | -2.13% |
| 2022 FY | 441.69 Million USD | 6.55% |
| 2022 Q2 | 463.32 Million USD | 3.77% |
| 2022 Q3 | 451.32 Million USD | -2.59% |
| 2021 Q3 | 381.45 Million USD | 8.94% |
| 2021 FY | 414.54 Million USD | 39.29% |
| 2021 Q1 | 321.34 Million USD | 7.97% |
| 2021 Q2 | 350.15 Million USD | 8.97% |
| 2021 Q4 | 414.54 Million USD | 8.67% |
| 2020 Q3 | 292.32 Million USD | -2.47% |
| 2020 Q2 | 299.74 Million USD | 2.61% |
| 2020 Q1 | 292.11 Million USD | 6.5% |
| 2020 FY | 297.61 Million USD | 8.5% |
| 2020 Q4 | 297.61 Million USD | 1.81% |
| 2019 FY | 274.28 Million USD | 2.03% |
| 2019 Q4 | 274.28 Million USD | -2.38% |
| 2019 Q3 | 280.97 Million USD | -1.87% |
| 2019 Q2 | 286.34 Million USD | 1.51% |
| 2019 Q1 | 282.08 Million USD | 4.93% |
| 2018 Q2 | 270.04 Million USD | -2.97% |
| 2018 Q1 | 278.31 Million USD | 8.98% |
| 2018 FY | 268.82 Million USD | 5.26% |
| 2018 Q4 | 268.82 Million USD | -3.05% |
| 2018 Q3 | 277.26 Million USD | 2.67% |
| 2017 Q2 | 253.73 Million USD | 4.69% |
| 2017 Q4 | 255.39 Million USD | -3.09% |
| 2017 FY | 255.39 Million USD | 15.02% |
| 2017 Q1 | 242.37 Million USD | 9.15% |
| 2017 Q3 | 263.52 Million USD | 3.86% |
| 2016 FY | 222.04 Million USD | 3.57% |
| 2016 Q3 | 239.98 Million USD | 2.56% |
| 2016 Q1 | 227.32 Million USD | 6.04% |
| 2016 Q4 | 222.04 Million USD | -7.47% |
| 2016 Q2 | 234 Million USD | 2.94% |
| 2015 Q3 | 225.54 Million USD | 1.02% |
| 2015 FY | 214.38 Million USD | 4.82% |
| 2015 Q4 | 214.38 Million USD | -4.95% |
| 2015 Q2 | 223.27 Million USD | 2.11% |
| 2015 Q1 | 218.66 Million USD | 6.91% |
| 2014 Q1 | 224.42 Million USD | 6.66% |
| 2014 Q2 | 224.44 Million USD | 0.01% |
| 2014 Q3 | 219.71 Million USD | -2.11% |
| 2014 Q4 | 204.53 Million USD | -6.91% |
| 2014 FY | 204.53 Million USD | -2.8% |
| 2013 Q4 | 210.41 Million USD | -4.0% |
| 2013 Q2 | 203.28 Million USD | 1.86% |
| 2013 Q3 | 219.17 Million USD | 7.82% |
| 2013 Q1 | 199.57 Million USD | 0.32% |
| 2013 FY | 210.41 Million USD | 5.77% |
| 2012 FY | 198.93 Million USD | 0.0% |
| 2012 Q4 | 198.93 Million USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| uniQure N.V. | 12.02 Million USD | -3109.123% |
| Agios Pharmaceuticals, Inc. | 19.07 Million USD | -1922.777% |
| Amicus Therapeutics, Inc. | 59.69 Million USD | -546.383% |
| Atara Biotherapeutics, Inc. | 9.7 Million USD | -3875.531% |
| bluebird bio, Inc. | 22.91 Million USD | -1583.603% |
| Cara Therapeutics, Inc. | 2.82 Million USD | -13578.306% |
| Imunon, Inc. | - USD | -Infinity% |
| Editas Medicine, Inc. | - USD | -Infinity% |
| IQVIA Holdings Inc. | - USD | -Infinity% |
| Myriad Genetics, Inc. | 20.1 Million USD | -1819.726% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | -907.48% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | -398.482% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 95.362% |
| Waters Corporation | 516.23 Million USD | 25.254% |
| Thermo Fisher Scientific Inc. | 5.08 Billion USD | 92.416% |
| Biogen Inc. | 2.52 Billion USD | 84.733% |
| Nektar Therapeutics | 16.1 Million USD | -2296.528% |
| Perrigo Company plc | 1.14 Billion USD | 66.179% |
| Dynavax Technologies Corporation | 53.29 Million USD | -624.085% |
| Illumina, Inc. | 587 Million USD | 34.265% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Iovance Biotherapeutics, Inc. | 10.37 Million USD | -3620.256% |
| Heron Therapeutics, Inc. | 42.11 Million USD | -816.326% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 65.149% |
| Sangamo Therapeutics, Inc. | - USD | -Infinity% |
| Evolus, Inc. | 10.99 Million USD | -3408.502% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Aclaris Therapeutics, Inc. | - USD | -Infinity% |
| Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 85.047% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | -488.003% |
| FibroGen, Inc. | 41.56 Million USD | -828.341% |
| Agilent Technologies, Inc. | 1.03 Billion USD | 62.574% |
| OPKO Health, Inc. | 65.69 Million USD | -487.34% |
| Homology Medicines, Inc. | - USD | -Infinity% |
| Geron Corporation | - USD | -Infinity% |
| Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | -332.846% |
| Exelixis, Inc. | 17.32 Million USD | -2127.472% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | - USD | -Infinity% |
| Zoetis Inc. | 2.56 Billion USD | 84.951% |
| Axsome Therapeutics, Inc. | 15.13 Million USD | -2449.488% |
| Abeona Therapeutics Inc. | -2.44 Million USD | 15888.257% |
| Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 47.771% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 28.42 Million USD | -1257.485% |
| Sarepta Therapeutics, Inc. | 322.85 Million USD | -19.515% |
| Corcept Therapeutics Incorporated | 7.73 Million USD | -4891.785% |
| Halozyme Therapeutics, Inc. | 127.6 Million USD | -202.4% |
| Blueprint Medicines Corporation | 21.22 Million USD | -1718.145% |
| Insmed Incorporated | 83.24 Million USD | -363.513% |
| TG Therapeutics, Inc. | 39.82 Million USD | -868.95% |
| Incyte Corporation | 62.97 Million USD | -512.756% |
| Emergent BioSolutions Inc. | 328.9 Million USD | -17.32% |